维奈克拉联合3+7柔红霉素和阿糖胞苷化疗作为成人急性髓系白血病一线治疗:多中心单臂2期试验
这项在中国三家公立医院开展的两阶段单臂2期试验,纳入33例18-60岁初治急性髓系白血病成人患者,给予DAV方案诱导治疗。一个疗程后复合完全缓解率为91%(95%CI 76-98),达完全缓解者中97%可测残留病阴性,1年总生存率97%。
要点
- DAV方案诱导一个疗程后复合完全缓解率为91%(95%CI 76-98;33例中30例)。
- 达完全缓解的30例中29例(97%)可测残留病阴性(<0.1%)。
- 3级及以上不良事件包括中性粒细胞减少、血小板减少和贫血各33例(100%),发热性中性粒细胞减少18例(55%)。
核心结论
- DAV方案是初诊成人急性髓系白血病有效的诱导治疗,完全缓解率高。
- 这些发现表明将维奈克拉纳入国际最常用初诊急性髓系白血病诱导方案是安全的策略。
研究设计与样本
- 两阶段、单臂、2期试验,在中国三家公立医院开展。
- 纳入33例18-60岁初治原发急性髓系白血病、ECOG体能状态0-2分的患者。
- 诱导治疗为DAV方案:第1-3天静脉柔红霉素60 mg/m2,第1-7天静脉阿糖胞苷100 mg/m2,第4天口服维奈克拉100 mg、第5天200 mg、第6-11天400 mg。
- 诱导治疗每周期28-35天,治疗1或2个周期;主要终点为诱导治疗一个周期后的复合完全缓解率,在按治疗人群中评估。
主要发现
- 2020年12月25日至2021年7月7日,36例患者评估合格,33例入组;15例(45%)为男性,18例(55%)为女性,均为亚洲人。
- DAV方案一个周期后复合完全缓解率为91%(95%CI 76-98;33例中30例)。
- 达完全缓解的30例中29例(97%)可测残留病不可测(即<0.1%)。
- 中位随访11个月(IQR 9-12),估计1年总生存率为97%(95%CI 91-100),1年无事件生存率为72%(95%CI 56-94)。
- 3级或更差不良事件包括中性粒细胞减少33例(100%)、血小板减少33例(100%)、贫血33例(100%)、发热性中性粒细胞减少18例(55%)、肺炎7例(21%)、脓毒症4例(12%);无治疗相关死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adults with acute myeloid leukaemia have unsatisfactory clinical outcomes and rates of complete remission. Venetoclax combined with azacytidine or low-dose cytarabine has shown efficacy in adults aged 75 years or older (or 18-74 years with comorbidities precluding intensive chemotherapy) with acute myeloid leukaemia. We aimed to investigate the activity and safety of venetoclax plus 3+7 daunorubicin and cytarabine chemotherapy in adults with acute myeloid leukaemia. METHODS: We conducted a two-stage, single-arm, phase 2 trial at three public hospitals in China. We enrolled patients aged 18-60 years with previously untreated de novo acute myeloid leukaemia and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received induction treatment with intravenous daunorubicin (60 mg/m2 on days 1-3), intravenous cytarabine (100 mg/m2 on days 1-7), and oral venetoclax (100 mg on day 4, 200 mg on day 5, and 400 mg on days 6-11; DAV regimen). For induction therapy, the length of the treatment was 28-35 days per cycle and the number of treatment cycles was one or two. The primary endpoint was the composite complete remission rate (complete remission plus complete remission with incomplete blood cell count recovery) after one cycle of induction treatment, assessed in the as-treated population. Secondary endpoints were bone marrow measurable residual disease by flow cytometry, event-free survival, overall survival, and adverse events. This trial is ongoing and is registered with Chinese Clinical Trial Registry, ChiCTR2000041509. FINDINGS: Between Dec 25, 2020, and July 7, 2021, 36 patients were assessed for eligibility and 33 were enrolled. 15 (45%) patients were men and 18 (55%) were women, and all were Asian. The composite complete remission rate after one cycle of DAV regimen was 91% (95% CI 76-98; 30 of 33 patients) in the entire cohort. 29 (97%) of 30 patients who reached complete remission had undetectable measurable residual disease (ie, <0·1%). Grade 3 or worse adverse events included neutropenia in 33 (100%) of 33 patients, thrombocytopenia in 33 (100%), anaemia in 33 (100%), febrile neutropenia in 18 (55%), pneumonia in seven (21%), and sepsis in four (12%). No treatment-related deaths occurred. With a median follow-up of 11 months (IQR 9-12), estimated 1-year overall survival was 97% (95% CI 91-100) and 1-year event-free survival was 72% (56-94). INTERPRETATION: The DAV regimen represents an effective induction therapy for newly diagnosed adults with acute myeloid leukaemia, which resulted in a high rate of complete remission. These findings are an important contribution to the field, showing a safe strategy to incorporate venetoclax into the most common induction regimen used to treat newly diagnosed acute myeloid leukaemia internationally. FUNDING: Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang, National Natural Science Foundation of China, Key Research and Development Program of Zhejiang. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Wang H, Mao L, Yang M, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022. PMID: 35512726. doi:10.1016/S2352-3026(22)00106-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。